OLICLINOMEL N7-1000E EMULSION FOR INFUSION

Package leaflet: information for the user
Oliclinomel N7-1000E, Emulsion for Infusion
Read all of this leaflet carefully before you are given this medicine, because it contains important
information for you.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or nurse.
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects
not listed in this leaflet. See section 4.
What is in this leaflet
1.
2.
3.
4.
5.
6.

1.

What OLICLINOMEL is and what it is given for
What you need to know before you are given OLICLINOMEL
How you will be given OLICLINOMEL
Possible side effects
How to store OLICLINOMEL
Contents of pack and other information

What OLICLINOMEL is and what it is given for

OLICLINOMEL is an emulsion for infusion. It is presented in a bag with 3 chambers.
One chamber contains a glucose solution with calcium, the second one contains a lipid
emulsion and the third one contains an amino acid solution with electrolytes.
Pharmacotherapeutic group: Solutions for parenteral nutrition/combinations
OLICLINOMEL is given to provide nutrition in adults and children greater than two years of age by a
tube into a vein when normal feeding by mouth is not suitable.
OLICLINOMEL must only be given under medical supervision.

2.

What you need to know before you are given OLICLINOMEL, emulsion for infusion

Do not use OLICLINOMEL and tell your doctor if:
-

the patient is a premature baby, an infant or a child less than 2 years old.
you are hypersensitive (allergic) to egg, soybean or peanuts proteins or to any other ingredient of
OLICLINOMEL.
your body has problems using amino acids.
you have especially high level of fats in your blood (hyperlipidaemia).
you have severe hyperglycaemia (too much sugar in your blood).
you have abnormally high amount of any of the electrolytes ( sodium, potassium, magnesium,
calcium and/ or phosphorus) in your blood

In all cases, your doctor will base his/her decision on whether you should receive this medicine on
factors such as age, weight and clinical condition, together with the results of any tests performed.
Warnings and precautions
Talk to your doctor or nurse before OLICLINOMEL is given to you.

If you are given total parenteral nutrition (TPN) solutions too fast this may result in death.
If any abnormal signs or symptoms of an allergic reaction develop, such as fever, chills, skin rashes or
difficulty in breathing, excessive sweating, nauseas and headache, the infusion will be stopped
immediately. This medicinal product contains soybean oil and egg phosphatide proteins. Soybean and
egg proteins may cause hypersensitivity reactions. Cross-allergic reactions between soybean and
peanut proteins have been observed.
Difficulty breathing could also be a sign that small particles have formed, blocking blood vessels in
the lungs (pulmonary vascular precipitates). If you experience any difficulty breathing, tell your doctor
or nurse. They will decide a course of action to be taken.
The antibiotic named ceftriaxone must not be mixed or given simultaneously with any calcium
containing solutions (including OLICLINOMEL) given to you by a drip into your vein.
These drugs must not be given to you together even via different infusion lines or different infusion
sites.
However, you may be given OLICLINOMEL and ceftriaxone sequentially one after another if
infusion lines at different sites are used or if the infusion lines are replaced or were thoroughly flushed
with physiological salt solution between the infusions to avoid precipitation (formation of particles of
ceftriaxone-calcium salt).
Your physician will be checking and monitoring the levels of your triglycerides (a type of fat found in
blood).
Certain medications and illnesses can increase the risk of developing infection or sepsis (bacteria in
the blood). There is a particular risk of infection or sepsis when a tube (intravenous catheter) is placed
in your vein. Your doctor will carefully watch you for any signs of infection. Patients who require
parenteral nutrition (giving nutrition through a tube in your vein) can be more likely to develop
infection from their medical conditions. Using “aseptic technique” (“germ free “) techniques when
placing and maintaining the catheter and when making the nutritional formula can reduce the risk of
infection.
Your doctor should be aware of:
- a severe kidney problem. You also must inform your doctor if you are on dialysis (artificial kidney)
or if you have another form of blood cleaning treatment
- a severe liver problem
- a blood clotting problems
- adrenal glands that are not working properly (adrenal insufficiency). The adrenal glands are triangleshaped glands located on top of your kidneys
- heart failure
- lung disease
- a build up of water in your body (hyperhydration)
- not enough water in your body (dehydration)
- high blood sugar (diabetes mellitus) that you are not being treated for
- a heart attack or shock due to a sudden heart failure
- a severe metabolic acidosis (when the blood is too acid)
- a generalised infection (septicaemia)
- coma.
If the patient is a child, the doctor will closely check their fluid status and/or blood values.
Fat overload syndrome has been reported with similar products. The reduced or limited ability of the
body to remove the fats contained in OLICLINOMEL may result in a "fat overload syndrome" (see
section 4 – Possible Side Effects).

No additions should be made to the bag without first checking the compatibility. Formation of
particles or a breaking down of the lipid emulsion could result. This can lead to blockage of the blood
vessels.
If your blood sugar gets too high, your doctor should adjust the rate of OLICLINOMEL delivery or
give you insulin.
If you are severely malnourished such that you need to receive feedings by vein, it is recommended
that parenteral nutrition is started slowly and carefully.
The balance of water and salt in your body and metabolic disorders will be corrected before starting
the infusion. Your doctor will monitor your condition while you receive this medicine and may change
the dosage or give you additional nutrients such as vitamins, electrolytes and trace elements if he/she
feels they are appropriate.
To check the effectiveness and ongoing safety of the administration, your doctor will perform clinical
and laboratory tests while you are receiving this medicine. If you are given this medicine for several
weeks, your blood will be monitored on a regular basis. These tests are particularly required in case
you suffer from certain conditions, such as a liver disorder, a kidney disorder, a disorder whereby
amino acids cannot be processed by the body, a disorder in which the blood becomes too acidic, a
disorder in which the level of fats and cholesterol is higher than normal, diabetes, or if you suffer from
anaemia or difficulty to stop bleeding.
During the infusion if you notice pain, burning, stiffness, swelling or skin discoloration at the infusion
site, or leakage of the infusion, tell your doctor or nurse. The administration will be stopped
immediately and restarted in another vein.
Children
If the patient is a child, special care will be taken to give the correct dosage. Vitamin and trace element
supplementation may be required depending on dose and duration. Increased precautions will also be
taken because of the greater sensitivity of children to the risk of infection.
Other medicines and OLICLINOMEL
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.
OLICLINOMEL must not be administered together with blood through the same infusion tubing.
OLICLINOMEL contains calcium. It should not be given together or through the same tube with the
antibiotic ceftriaxone because particles may form. If the same device is used to give you successively
these medicines, it should be thoroughly rinsed.

The olive and soybean oils present in OLICLINOMEL contain vitamin K. This does not normally
affect blood thinning medicines (anticoagulants) like coumarin. However, if you take anticoagulant
medicines you should tell your doctor.
The lipids contained in this emulsion may interfere with the results of certain laboratory tests if the
blood sample is taken before the lipids have been eliminated (these are generally eliminated after a
period of 5 to 6 hours without receiving lipids).
OLICLINOMEL with electrolytes contains potassium. Special care should be taken in patients taking
diuretics, ACE inhibitors or angiotensin II receptor antagonists (drugs for high blood pressure) or
immunosuppressants. These types of drugs may increase potassium levels in your blood.

Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor for advice before this medicine is given to you.

3.

How you will be given OLICLINOMEL

OLICLINOMEL should only be given in adults and children greater than 2 years of age.
It is an emulsion for infusion, that is given through a plastic tube into a large vein in your chest only.
The prescription may be continued for as long as it is needed, depending upon your clinical condition.
OLICLINOMEL is for single use only.
Dosage – Adults
Your doctor will decide the amount you are given depending on your individual needs and clinical
condition.
The maximum daily dose is 33 ml of emulsion / kg of body weight. For example: if you weigh 70 kg,
the maximum daily dose should not exceed 2310 ml of emulsion (33 ml of emulsion times 70 kg).
Dosage - Children greater than two years of age
Your doctor will decide the dose the child will need and for how long it will be given. This will
depend on age, weight, height, clinical condition, daily fluid volume, energy and nitrogen
requirements.
The maximum daily dose is 75 ml of emulsion / kg of body weight. For example: if the patient is a
child weighing 30 kg, the maximum daily dose should not exceed 2,250 ml of emulsion (75 ml of
emulsion times 30 kg).
If you are given more OLICLINOMEL than you should
If the dose given is too high or the infusion too fast, the amino acid content may make your blood too
acid and you may have too much fluid in the circulation. The glucose content may increase the glucose
in your blood and urine or the lipid content may increase the triglycerides in your blood. Giving a
volume of OLICLINOMEL that is too large may cause nausea, vomiting, chills and electrolyte
disturbances, in such situations the infusion should be stopped immediately.
In some severe cases, your doctor may have to give you temporary renal dialysis to help your kidneys
eliminate the excess product.
To prevent these events occurring, your doctor will regularly monitor your condition and test your
blood parameters.
If you have any further questions on the use of this product, ask your doctor.

4.

Possible side effects

Like all medicines, OLICLINOMEL can cause side effects, although not everybody gets them. If you
notice any changes in the way you feel during or after the treatment, tell your doctor or nurse right
away.
The tests your doctor will perform while you are taking the medicine are meant to minimise side
effects.

If any abnormal signs or symptoms of an allergic reaction develop, such as raised body temperature,
chills, skin rashes or breathing difficulties, excessive sweating, nauseas and headache, the infusion
should be stopped immediately.
The following side effects have been reported with OLICLINOMEL
Common (may affect up to 1 in 10 people):
Allergic reactions
Headache
Diarrhoea
Infusion site pain, swelling
Accumulation of fluid at infusion site
Abnormal blood test for the liver function.
Increased blood triglycerides (fat)
Frequency not known (cannot be estimated from the available data):
Constriction of the airway, breathing with whistling sound and/or cough (bronchospasm as part
of allergic reaction)
Fever
Tremor
Abdominal pain, chest pain, back pain, extremity pain
Vomiting, nausea
Increase in the size of the liver (hepatomegaly)
Jaundice (yellowish of the skin or white of the eyes caused by liver or blood problem)
Abnormal flushing of the skin (erythema)
Excessive sweating
Decrease in the number of platelets (reduction in number of cells in charge of blood clotting
which causes bleeding as nosebleed).
Increased blood glucose (sugar)
Death of tissue cells (necrosis) around the infusion site
A local defect of tissue, which can lead to necrosis (ulcer)
The following side effects have been reported with similar products:
Very rare (may affect up to 1 in 10,000 people):
The reduced or limited ability to remove the lipids contained in Oliclinomel may result in a "fat
overload syndrome". This may be caused by overdose but may also occur at the start of an infusion,
even if the product is administered according to instructions. It is associated with a sudden
deterioration in the patient's clinical condition. It is characterised by high level of fats in your blood,
fever, liver fatty infiltration (high level of fat in your liver), and/or an increase of your liver volume, an
anaemia (reduction in red blood cells which can make the skin pale and cause weakness or
breathlessness), a fall in white blood cells and blood platelets, problem with your blood clotting and/or
coma may also occur. The syndrome is usually reversible when the infusion of the lipid emulsion is
stopped.
Frequency not known (cannot be estimated from the available data):
Formation of small particles which may lead to blockage of blood vessels in the lungs (pulmonary
vascular precipitates) resulting in pulmonary vascular embolism and difficulty breathing (respiratory
distress).
Fall in white blood cells and blood platelets have been reported in children.

Reporting of side effects
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not
listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at:

www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this medicine
5.

How to store OLICLINOMEL

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the container and the outer packaging
after EXP. This expiry date refers to the last day of that month.
Do not freeze.
Keep the container in the outer carton in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help to protect the environment.

6.

Contents of the pack and other information

What OLICLINOMEL contains
The active substances for each bag of the reconstituted emulsion are:
Active substances
1000 ml
1500 ml
2000 ml
2500 ml
Refined soya bean oil + refined olive oil *
40.00 g
60.00 g
80.00 g
100.00 g
L-alanine
8.28 g
12.42 g
16.56 g
20.70 g
L-arginine
4.60 g
6.90 g
9.20 g
11.50 g
Glycine
4.12 g
6.18 g
8.24 g
10.30 g
L-histidine
1.92 g
2.88 g
3.84 g
4.80 g
L-isoleucine
2.40 g
3.60 g
4.80 g
6.00 g
L-leucine
2.92 g
4.38 g
5.84 g
7.30 g
L-lysine
2.32 g
3.48 g
4.64 g
5.80 g
(as lysine hydrochloride)
(2.90 g)
(4.35 g)
(5.80 g)
(7.25 g)
L-methionine
1.60 g
2.40 g
3.20 g
4.00 g
L-phenylalanine
2.24 g
3.36 g
4.48 g
5.60 g
L-proline
2.72 g
4.08 g
5.44 g
6.80 g
L-serine
2.00 g
3.00 g
4.00 g
5.00 g
L-threonine
1.68 g
2.52 g
3.36 g
4.20 g
L-tryptophan
0.72 g
1.08 g
1.44 g
1.80 g
L-tyrosine
0.16 g
0.24 g
0.32 g
0.40 g
L-valine
2.32 g
3.48 g
4.64 g
5.80 g
Sodium acetate, 3H 2 O
2.45 g
3.67 g
4.90 g
6.12 g
Sodium glycerophosphate, 5 H 2 O
2.14 g
3.22 g
4.29 g
5.36 g
Potassium chloride
1.79 g
2.68 g
3.58 g
4.47 g
Magnesium chloride, 6H 2 O
0.45 g
0.67 g
0.90 g
1.12 g
Glucose
160.00 g
240.00 g
320.00 g
400.00 g
(as glucose monohydrate)
(176.00 g)
(264.00 g)
(352.00 g)
(440.00 g)
Calcium chloride, 2H 2 O
0.30 g
0.44 g
0.59 g
0.74 g
Total calories (kcal)
1200
1800
2400
3000
Non-protein calories (kcal)
1040
1560
2080
2600
* Mixture of refined olive oil (approximately 80%) and refined soya bean oil (approximately 20%).
The other ingredients are purified egg phosphatide, glycerol, sodium oleate, sodium hydroxide, glacial
acetic acid, hydrochloric acid, water for injections.

What OLICLINOMEL looks like and contents of the pack
OLICLINOMEL is an emulsion for infusion package in a 3-chamber bag, which is a multi-layer
plastic bag. The inner (contact) layer of the bag material is made from polymers (blend of polyolefinic
copolymers) compatible with constituent (amino acid solutions, glucose solutions and lipid emulsions)
and authorized additives and allowing to make peelable seals. The polymers used for the entire film
structure are made of EVA (poly(ethylene-vinyl acetate)), and of a copolyester.
Before the contents of the 3 chambers in the bag are mixed, 1 chamber contains a homogenous liquid
with a milky appearance (the lipid emulsion), while the two other chambers (containing the amino acid
solution with electrolytes and the glucose solution with calcium chloride) contain a colourless or
lightly yellow solution, practically free of visible particles. Once mixed, OLICLINOMEL is an
emulsion for infusion which looks like a homogenous and milky-white liquid.
To prevent contact with oxygen from the air the bag is packaged in an oxygen barrier overpouch,
which contains an oxygen absorber sachet.
Pack sizes
1000 ml bag: 1 bag or carton with 6 bags
1500 ml bag: 1 bag or carton with 4 bags
2000 ml bag: 1 bag or carton with 4 bags
2500 ml bag: 1 bag or carton with 2 bags
Not all pack sizes may be marketed.
Marketing Authorisation Holder
For any information about OLICLINOMEL, please contact the Marketing Authorisation Holder:
Baxter Healthcare Limited
Caxton Way
Thetford
Norfolk, IP24 3SE
United Kingdom
Manufacturer
Baxter S.A., Boulevard René Branquart, 80, 7860 Lessines, Belgium
This medicinal product is authorised in the Member States of the EEA under the following
names:
Oliclinomel N7-1000E
In some countries it is registered under a different trade name, as described below:
Austria and Germany: Oliclinomel 4% GF-E

This leaflet was last revised in
11/2015

-------------------------------------------------------------------------------------------------------------The following information is intended for healthcare professionals only:
Oliclinomel N7-1000E, Emulsion for Infusion
1.

Quantitative composition

After the contents of the 3 compartments have been mixed, the appearance of the mixture is a
homogenous milk-like emulsion. The mixed emulsion for each of the different bag presentations
provides the following:
Per bag
1000 ml
Nitrogen (g)
6.6
Amino acids (g)
40
Glucose (g)
160
Lipids (g)
40
Total calories (kcal)
1200
Non-protein calories (kcal)
1040
Glucose calories (kcal)
640
Lipid calories (kcal)
400
Non-protein calorie/nitrogen ratio (kcal/g N)
158
Sodium (mmol)
32
Potassium (mmol)
24
Magnesium (mmol)
2.2
Calcium (mmol)
2
Phosphate (mmol)**
10
Acetate (mmol)
57
Chloride (mmol)
48
pH
6
Osmolarity (mOsm/l)
1450
** Including phosphates provided by the lipid emulsion
2.

1500 ml
9.9
60
240
60
1800
1560
960
600
158
48
36
3.3
3
15
86
72
6
1450

2000 ml
13.2
80
320
80
2400
2080
1280
800
158
64
48
4.4
4
20
114
96
6
1450

2500 ml
16.5
100
400
100
3000
2600
1600
1000
158
80
60
5.5
5
25
143
120
6
1450

Posology and method of administration

The dosage depends on the patient’s energy expenditure, clinical status, body weight, and the ability to
metabolize the constituents of OLICLINOMEL, as well as additional energy or proteins provided
orally/enterally; therefore, the bag size should be chosen accordingly.
The administration may be continued for as long as is required by the patient’s clinical conditions.
The maximum daily dose should not be exceeded in adult and pediatric patients. Due to the static
composition of the multi-chamber bag, the ability to simultaneously meet all nutrient needs of the
patient may not be possible. Clinical situations may exist where patients require amounts of nutrients
varying from the composition of the static bag.
As a general rule do not exceed doses of 3g/kg/day amino acids and /or 17 g/kg/day glucose and/or 3
g/kg/day lipids and/or 100mml/kg/day fluid, except in particular cases.
OLICLINOMEL is for single use only.
The recommended duration of the parenteral nutrition infusion is between 12 and 24 hours.

Dosage and infusion rate– Adults
Average nitrogen requirements are 0.16 to 0.35 g/kg/day (approximately 1 to 2 g amino acids/kg/day).
Energy requirements vary depending on the patient's nutritional state and level of catabolism. On
average these are 20 to 40 kcal/kg/day.
Maximum daily dose:
The maximum daily dose is defined by the energy component.The maximum daily dose is 33 ml/kg
body weight (equivalent to 1.32 g amino acids, 5.28 g glucose, 1.32 g lipids, 1.06 mmol sodium and
0.79 mmol potassium / kg), i.e. 2310 ml of the emulsion for infusion for a patient weighing 70 kg.
Maximum infusion rate:
As a general rule do not exceed infusion rates of 0.10 g/kg/hour amino acids and/or 0.25 g/kg/hour
glucose and/or 0.15 g/kg/hour lipids, except in particular cases.
As a general rule, do not exceed 1.5 ml/kg/hour of the emulsion for infusion, i.e. 0.06 g amino acids,
0.24 g glucose and 0.06 g lipids / kg body weight / hour.
The recommended duration of the parenteral nutrition infusion is between 12 and 24 hours. Normally,
the flow rate is increased gradually during the first hour without exceeding 1.5 ml / kilogram of your
body weight / hour, and the maximal dose is 36 ml/ kilogram of your body weight / day.
Dosage and infusion rate – Adolescents and children greater than 2 years of age
There have been no studies performed in the pediatric population.
Children 2-11 years of age: Average nitrogen requirements are 0.16 to 0.35 (up to 0.45) g/kg/day
equivalent to 1-2 (up to 3) g amino acids/kg/day
Children 12-18 years of age: Average nitrogen requirements are 0.16 to 0.35 g/kg/day equivalent to 12 g amino acids/kg/day.
.
Energy requirements vary depending on the patient's age, nutritional state and level of catabolism. On
average these range between:
Children 2-11 years of age: 60 – 90 kcal/kg/day
Children 12-18 years of age: 30 - 75 kcal/kg/day.
The dosage is based on fluid intake and daily nitrogen requirements.
These intakes should be adjusted to take account of the child's hydration status.
Maximum daily dose:
The maximum daily dose is 75 ml/kg body weight (equivalent to 3 g amino acids, 12 g glucose, 3 g
lipids, 2.4 mmol sodium and 1.8 mmol potassium / kg body weight).
Maximum infusion rate in children 2-11 years of age:
In this group of age, the limiting factor for hourly rate is the lipid concentration. As a general rule, do
not exceed 3.3 ml/kg/hour of the emulsion for infusion, i.e. 0.13 g amino acids, 0.52 g glucose and
0.13 g lipids/kg body weight /hour.
Maximum infusion rate in children 12-18 years of age:
In this group of age, the limiting factor for hourly rate is the lipid concentration. As a general rule, do
not exceed 3.0 ml/kg/hour of the emulsion for infusion, i.e. 0.12 g amino acids, 0.48 g glucose and
0.12 g lipids/kg body weight /hour.
As a general rule, the maximum infusion rates are:
Children 2-11 years of age: 0.20 g/kg/hour amino acids and/or 1.20 g/kg/hour glucose and/or 0.13
g/kg/hour lipids, except in particular cases.

Children 12-18 years of age: 0.12 g/kg/hour amino acids and/or 1.20 g/kg/hour glucose and/or 0.13
g/kg/hour lipids, except in particular cases.
Route of administration
OLICLINOMEL must be administered intravenously through a central vein.
The administration flow rate should be adjusted to take account of the dose being administered, the
characteristics of the final mixture being infused, the daily volume intake and the duration of the
infusion.

3.

Special warnings and precautions for use

-

Do not administer through a peripheral vein

-

An excessively fast administration of total parenteral nutrition (TPN) solutions, including
OLICLINOMEL, may result in severe or fatal consequences.

-

The infusion must be stopped immediately if any abnormal signs or symptoms of an allergic
reaction (such as sweating, fever, chills, headache, skin rashes, dyspnoea or bronchospasm)
develop. This medicinal product contains soybean oil and egg phosphatide. Soybean and egg
proteins may cause hypersensitivity reactions. Cross-allergic reactions between soybean and
peanut proteins have been observed.

-

Severe water and electrolyte equilibration disorders, severe fluid overload states, and severe
metabolic disorders must be corrected before starting the infusion.

-

Specific clinical monitoring is required when an intravenous infusion is started.

–

Ceftriaxone must not be mixed or administered simultaneously with any calcium-containing IV
solutions even via different infusion lines or different infusion sites. Cefriaxone and calciumcontaining solutions may be administered sequentially one after another if infusion lines at
different sites are used or if the infusion lines are replaced or thoroughly flushed between
infusions with physiological salt solution to avoid precipitation. In patients requiring continuous
infusion with calcium-containing TPN solutions, healthcare professionals may wish to consider
the use of alternative antibacterial treatments which do not carry a similar risk of precipitation.
If use of ceftriaxone is considered necessary in patients requiring continuous nutrition, TPN
solutions and ceftriaxone can be administered simultaneously, albeit via different infusion lines
at different sites. Alternatively, infusion of TPN solution could be stopped for the period of
ceftriaxone infusion, considering the advice to flush infusion lines between solutions (see
section 4, “Interactions” and ”Incompatibilities”).

–

Pulmonary vascular precipitates causing pulmonary vascular embolism and respiratory distress
have been reported in patients receiving parenteral nutrition. In some cases, fatal outcomes have
occurred. Excessive addition of calcium and phosphate increases the risk of the formation of
calcium phosphate precipitates (see section 4, “Incompatibilities”).

-

Do not add other medicinal products or substances to any components of the bag or to the
reconstituted emulsion without first confirming their compatibility and the stability of the
resulting preparation (in particular the stability of the lipid emulsion). Formation of precipitates
or destabilization of the lipid emulsion could result in vascular occlusion.

-

Vascular access infection and sepsis are complications that may occur in patients receiving
parenteral nutrition, particularly in case of poor maintenance of catheters, immunosuppressive
effects of illness or drugs. Careful monitoring of signs, symptoms, and laboratory tests for
fever/chills, leukocytosis, technical complications with the access device and hyperglycaemia
can help recognize early infections. Patients who require parenteral nutrition are often

predisposed to infectious complications due to malnutrition and/or their underlying disease
state. The occurrence of septic complications can be decreased with heightened emphasis on
aseptic techniques in catheter placement, maintenance, as well as aseptic techniques in the
preparation of the nutritional formula
-

Monitor water and electrolyte balance, serum osmolarity, serum triglycerides, acid-base
balance, blood glucose, liver and kidney function, and blood count, including platelets and
coagulation parameters throughout treatment.

-

Metabolic complications may occur if the nutrient intake is not adapted to the patient's
requirements, or the metabolic capacity of any given dietary component is not accurately
assessed. Adverse metabolic effects may arise from administration of inadequate or excessive
nutrients or from inappropriate composition of an admixture for a particular patient's needs.

-

Serum triglyceride concentrations and the ability of the body to remove lipids must be checked
regularly.

-

Serum triglyceride concentrations must not exceed 3 mmol/l during the infusion. These
concentrations should not be determined before a minimum of a 3-hour period of continuous
infusion.

-

If a lipid metabolism abnormality is suspected, it is recommended that tests be performed daily
by measuring serum triglycerides after a period of 5 to 6 hours without administering lipids. In
adults, the serum must be clear in less than 6 hours after stopping the infusion containing the
lipid emulsion. The next infusion should only be administered when the serum triglyceride
concentrations have returned to normal values.

-

Fat overload syndrome has been reported with similar products. The reduced or limited ability
to metabolize the lipids contained in OliClinomel may result in a "fat overload syndrome"
which may be caused by overdose; however the signs and symptoms of this syndrome may also
occur when the product is administered according to instructions.

-

In the event of hyperglycaemia, the infusion rate of OLICLINOMEL must be adjusted and/or
insulin administered.

-

While OLICLINOMEL N4-550, N4-550E may be administered through a peripheral vein,
thrombophlebitis may develop. The catheter insertion site must be monitored daily for local
signs of thrombophlebitis.

-

When making additions, the final osmolarity of the mixture must be measured before
administration. The mixture obtained should be administered through a central or peripheral
venous line depending on its final osmolarity. If the final mixture administered is hypertonic, it
may cause irritation of the vein when administered into a peripheral vein.

-

Although there is a natural content of trace elements and vitamins in the product, the levels are
insufficient to meet body requirements and these should be added to prevent deficiencies from
developing. See instructions for making additions to this product.

-

Caution should be exercised in administering OLICLINOMEL to patients with increased
osmolarity, adrenal insufficiency, heart failure or pulmonary dysfunction

-

Refeeding severely undernourished patients may result in the refeeding syndrome that is
characterized by the shift of potassium, phosphorus, and magnesium intracellularly as the
patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. Careful
monitoring and slowly increasing nutrient intakes while avoiding overfeeding can prevent these
complications. This syndrome has been reported with similar products.

-

Do not connect bags in series in order to avoid air embolism due to residual air contained in the
primary bag.

Hepatic Insufficiency
Use with caution in patients with hepatic insufficiency because of the risk of developing or worsening
neurological disorders associated with hyperammonaemia. Regular clinical and laboratory tests are
required particularly controlling liver function parameters, blood glucose, electrolytes and
triglycerides.
Renal Insufficiency
Use with caution in patients with renal insufficiency, particularly if hyperkalaemia is present, because
of the risk of developing or worsening metabolic acidosis and hyperazotemia if extra-renal waste
removal is not being performed. Fluid triglycerides and electrolyte status should be closely monitored
in these patients.
Hematologic
Use with caution in patients with coagulation disorders and anaemia. Blood count and coagulation
parameters should be closely monitored.
Endocrine and Metabolism
Use with caution in patients with:
• Metabolic acidosis. Administration of carbohydrates is not recommended in the presence of
lactic acidosis. Regular clinical and laboratory tests are required.
• Diabetes mellitus. Monitor glucose concentrations, glucosuria, ketonuria and, where
applicable adjust insulin dosages.
 Hyperlipidaemia due to the presence of lipids in the emulsion for infusion. Regular clinical
and laboratory tests are required.
 Amino acid metabolism disorders
Extravasation
Catheter site should be monitored regularly to identify signs of extravasation. If extravasation occurs,
the administration should be stopped immediately, keeping the inserted catheter or cannula in place for
immediate management of the patient. If possible, aspiration should be performed through the inserted
cathter/ cannula, in order to reduce the amount of fluid present in the tissues before removing the
catheter/ cannula.
Depending on the extravasated product (including the product(s) being mixed with OLICLINOMEL,
if applicable) and the stage/extent of any injury, appropriate specific measures should be taken.
Options for management may include non-pharmacologic, pharmacologic and/or surgical
intervention. If there is any deterioration of the affected area (continued pain, necrosis, ulceration,
suspected compartment syndrome), surgery should be consulted immediately.
The extravasation site should be monitored at least every 4 hours during the 24 first hours, then once
daily.
The administration should not be restarted in the same central vein.
Special precautions in paediatrics
When administered to children greater than 2 years old, it is essential to use a bag which has a volume
corresponding to the daily dosage.
Vitamin and trace element supplementation is always required. Paediatric formulations should be
used.

4.

Practical information on preparation and handling

Only use OLICLINOMEL if:
the bag is undamaged,
the non-permanent seals are intact,
the glucose and amino acid solutions are clear, colourless or slightly yellow, practically free of
visible particles
the lipid emulsion is homogeneous and milk-like.
OLICLINOMEL should be at room temperature before use.
Only administer the product after the non-permanent seals between the 3 compartments have been
broken and the contents of the 3 compartments have been mixed as shown below.
Ensure that the final emulsion for infusion does not show any evidence of phase separation.
1.

2.

3.

Tear from the top to open the
overpouch.

Peel the front of the overpouch
to reveal the OLICLINOMEL
bag. Discard the overpouch and
oxygen absorber sachet.

Place the bag flat on a
horizontal and clean surface
with handle in front of you.

4.

5.

6.

Lift the hanger area to remove
solution from the upper bag.
Firmly roll the upper bag until
peal seal is fully open
(approximately half way).

Mix by turning the bag upsidedown at least 3 times. Ensure a
homogenous mixture, with no
evidence of phase separation

Hang the bag. Twist off the
protector from the
administration outlet. Firmly
plug the spike connector.

After opening the bag, the content must be used immediately. The opened bag must never be stored
for a subsequent infusion.
Do not reconnect any partially used bag.
Do not connect bags in series in order to avoid the possibility of air embolism due to air contained in
the primary bag.
For single use only. Any unused product or waste material and all necessary devices must be
discarded.
Do not store any partially used bags and discard all devices after use.

Supplementation
Do not add other medicinal products or substances to any components of the bag or to the
reconstituted emulsion without first confirming their compatibility and the stability of the resulting
preparation (in particular stability of the lipid emulsion).
However, OLICLINOMEL can be used as such or after supplementation with electrolytes, trace
elements or vitamins, when required.
The capacity of the bag is sufficient to enable additions such as, vitamins, electrolytes, and trace
elements. Any additions (including vitamins) may be made into the reconstituted mixture (after the
non-permanent seals have been opened and the contents of the three compartments have been mixed).
Vitamins may also be added into the glucose compartment before the mixture has been reconstituted
(before opening the non-permanent seals and before mixing the solutions and the emulsion).
When making additions to the formulation, the final osmolarity of the mixture should be measured
before administration via a peripheral vein
OLICLINOMEL may be supplemented with:
Electrolytes: electrolytes already present in the bag should be taken into account: stability has
been demonstrated up to a total quantity of 150 mmol of sodium, 150 mmol of potassium, 5.6
mmol of magnesium and 5 mmol of calcium per litre of the ternary mixture.
Organic phosphate: stability has been demonstrated for additions of up to 15 mmol per bag.
Trace elements and vitamins: Stability has been demonstrated with commercially available
preparations of vitamins and trace elements (containing up to 1 mg of iron). Compatibility for other
additives is available upon request.
Additions must be performed by qualified personnel under aseptic conditions.
These additions are made into the injection site using a needle:
Prepare the injection site,
Puncture the injection site and inject,
Mix the contents of the bag and the additives.
Interactions
No interaction studies have been performed with OLICLINOMEL.
OLICLINOMEL contains vitamin K, naturally present in lipid emulsions. The amount of Vitamin K in
recommended doses of Oliclinomel are not expected to influence effects of coumarin derivatives.
Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing
solutions, including OLICLINOMEL, because of the risk of precipitation of ceftriaxone-calcium salt.
Ceftriaxone and calcium-containing solutions may be administered sequentially one after another if
infusion lines at different sites are used or if the infusion lines are replaced or thoroughly flushed
between infusions with physiological salt-solution to avoid precipitation.
Due to the potassium content of OLICLINOMEL, special care should be taken in patients treated with
potassium sparing diuretics (e.g, amiloride, spironolactone, triamterene) angiotensin converting
enzyme (ACE) inhibitors, angiotensin II receptor antagonists or the immunosuppressants tacrolimus
and cyclosporine in view of the risk of hyperkalemia.
The lipids contained in this emulsion may interfere with the results of certain laboratory tests (for
example, bilirubin, lactate dehydrogenase, oxygen saturation, blood haemoglobin) if the blood sample
is taken before the lipids have been eliminated (these are generally eliminated after a period of 5 to 6
hours without receiving lipids).

Incompatibilities
This emulsion for infusion must not be administered simultaneously with blood through the same
infusion tubing.
OLICLINOMEL contains calcium ions which pose additional risk of coagulation precipitates in citrate
anticoagulated/preserved blood or components.
Incompatibilities may be produced for example by excessive acidity (low pH) or inappropriate content
of divalent cations (Ca2+ and Mg2+), which may de-stabilise the lipid emulsion.
As with any parenteral nutrition admixture, calcium and phosphate ratios must be considered. Excess
addition of calcium and phosphate, especially in the form of mineral salts, may result in formation of
calcium phosphate precipitates.
Check compatibility with solutions administered simultaneously through the same giving set, catheter
or cannula.
Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing
solutions, including OLICLINOMEL, because of the risk of precipitation of ceftriaxone-calcium salt
(see section Interactions).
5.

Shelf life

2 years if the overwrap is not damaged.
It is recommended that the product is used immediately after the non-permanent seals between the 3
compartments have been opened. The reconstituted emulsion has, however, been shown to be stable
for a maximum of 7 days at between +2o and +8oC followed by a maximum of 48 h at temperatures
not exceeding + 25oC.
After supplementation (electrolytes, trace elements, vitamins) of reconstituted OLICLINOMEL, (see
previous section), chemical and physical in-use stability has been demonstrated for 7 days at 2 to 8°C
followed by 48 hours below 25°C. From a microbiological point of view, any admixture should be
used immediately. If not used immediately, in-use storage times and conditions prior to use are the
responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless addition
of supplements has taken place in controlled and validated aseptic conditions.